DERM2026 Posters

Efficacy and Safety of Tapinarof Cream 1% Once Daily Monotherapy in Adults and Children with Atopic Dermatitis: Pooled Results from ADORING 1 and 2 Jonathan I. Silverberg, Lawrence F. Eichenfield, Linda Stein Gold, Juan Camilo Arjona Ferreira, Robert Bissonnette < PREVIOUS POSTER NEXT POSTER > POSTER 25

Tailoring Treatment With Abrocitinib: Personalized Treatment Approaches Used in the JADE REAL Study Raj Chovatiya, Stephan Weidinger, Pinaki Biswas, Melissa Watkins, Herwig Koppensteiner < PREVIOUS POSTER NEXT POSTER > POSTER 26

52 Week Safety and Efficacy of Amlitelimab in Participants With Moderate-to-Severe Atopic Dermatitis: Preliminary Analysis From the Open-Label Long-Term ATLANTIS Trial Emma Guttman-Yassky, Nina Magnolo, Maxwell Sauder, Delphine Staumont, Ken Igawa, Mahreen Ameen, Lin Ma, Lindsay Ackerman, Guy Gherardi, Pei Li, Melanie Espinasse, Karl Yen, Charlotte Bernigaud < PREVIOUS POSTER NEXT POSTER > POSTER 27

Efficacy and Safety of Monotherapy Amlitelimab, a Non-Depleting Anti-OX40 Ligand Antibody, in Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the Pivotal COAST-1 and COAST-2 Phase 3 Trials Linda Stein Gold, H. Chih-ho Hong, Pedro Mendes-Bastos, Nina Magnolo, Jinhua Xu, Ken Igawa, Guy Gherardi, Pei Li, Karl Yen, Charlotte Bernigaud, Benjamin Planquette < PREVIOUS POSTER NEXT POSTER > POSTER 28

Efficacy and Safety of Amlitelimab, a Nondepleting Anti-OX40 Ligand Antibody, in Combination With Topical Therapy in Participants With Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the SHORE Phase 3 Trial Eric Simpson, Stephan Weidinger, Michael Cameron, Thomas Hubiche, Xinghua Gao, Yoko Kataoka, Guy Gherardi, Pei Li, Karl Yen, Charlotte Bernigaud, Sonya Davey < PREVIOUS POSTER NEXT POSTER > POSTER 29

Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison Martin Steinhoff, DirkJan Hijnen, Vimal H. Prajapati, Jensen Yeung, Patricia Guyot, Yann Cabon, Yingxin Xu, Zhixiao Wang, Kerry Noonan, Mike Bastian < PREVIOUS POSTER NEXT POSTER > POSTER 30

Dupilumab Monotherapy Improves Xerosis and Dyspigmentation in Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis Andrew F. Alexis, Orit Markowitz, Tiffany Mayo, Valerie D. Callender, Noah A. Levit, Changming Xia, Chien-Chia Chuang, Brad Shumel, Zhixiao Wang, Christopher Hartford < PREVIOUS POSTER NEXT POSTER > POSTER 31

Systemic Treatments' Outcomes for Moderate-to-Severe Atopic Dermatitis in Children Aged Less Than 12 Years: PEDISTAD 5-Year Result Amy S. Paller, Joel C. Joyce, Alan D. Irvine, Lawrence F. Eichenfield, Lin Ma, Lara Wine Lee, Marlies de Graaf, Sara Hamad, Marius Ardeleanu, Annie Zhang < PREVIOUS POSTER NEXT POSTER > POSTER 32

Impact of Dupilumab on Bone Mineralization Biomarker and Growth in Girls and Boys 6–11 Years With Severe Atopic Dermatitis Alan D. Irvine, Amy S. Paller, Elaine C. Siegfried, Michael J. Cork, Lisa A. Beck, Lin Ma, Annamaria Staiano, Wenying Deng, Stephane Levy, Mike Bastian, Sonya L. Cyr < PREVIOUS POSTER NEXT POSTER > POSTER 33

Sustained Improvement in Signs and Symptoms of Atopic Dermatitis in Adolescents and Adults Initiating Dupilumab in Real-World Practice: 5-Year Completer Interim Analysis from the PROSE Registry Hermenio C. Lima, Luz Fonacier, Benjamin Lockshin, Tien Q. Nguyen, Yonghao Ma, Kwinten Bosman, Andrew Korotzer < PREVIOUS POSTER NEXT POSTER > POSTER 34

HRQoL and Work Productivity Improvements with Topical Delgocitinib vs Oral Alitretinoin in Chronic Hand Eczema: Phase 3 DELTA FORCE Results Andrea Bauer, Timo Buhl, Richard Woolf, James Greig, Jenny M. Norlin, Henrik Thoning, Ana Maria Giménez-Arnau < PREVIOUS POSTER NEXT POSTER > POSTER 35

Baseline Burden and Treatment History of Adolescents with Moderate-to-Severe Chronic Hand Eczema (CHE) Enrolled in the Randomized Phase 3 DELTA TEEN Trial Sonja Molin, Diana Rubel, Francisco J. Navarro-Triviño, Ziad Reguiai, Sofie De Schepper, James Halpern, Danielle Marcoux, John Su, Paweł Brzewski, F. Elcin Darendeli, Eydna Didriksen Apol, Henrik Thoning, Patrick Thøgersen, Lawrence F. Eichenfield < PREVIOUS POSTER NEXT POSTER > POSTER 36

The DELTA TEEN Phase 3 Trial: Systemic Exposure and Safety Profile of Delgocitinib Cream in Adolescents with Moderate-to-Severe Chronic Hand Eczema Sonja Molin, Eulalia Baselga, FJ Navarro-Triviño, Ziad Reguiai, Sofie De Schepper, James Halpern, Danielle Marcoux, John Su, Line Conradsen Hiort, Patrick Thøgersen, Diana Rubel < PREVIOUS POSTER NEXT POSTER > POSTER 37

Construction and Validation of a Photographic Guide for the Validated Investigator’s Global Assessment of Chronic Hand Eczema Scale (IGA-CHE) Andrea Bauer, Robert Bissonnette, Tove Agner, James Greig, Rie von Eyben, Jonathan Silverberg < PREVIOUS POSTER NEXT POSTER > POSTER 38

Sustained Health-Related Quality of Life improvements with Delgocitinib 20 mg/g Cream in Chronic Hand Eczema - Results from the Phase 3 Open-Label Extension DELTA 3 Trial April W. Armstrong, Linda Stein Gold, Andrea Bauer, James Greig, Jenny M. Norlin, Henrik Thoning, Tove Agner < PREVIOUS POSTER NEXT POSTER > POSTER 39

Efficacy and Safety of Litifilimab in Cutaneous Lupus Erythematosus (CLE): 24-Week Results of the Phase 2 Study, AMETHYST Part A Joseph F. Merola, Victoria P. Werth, Benjamin F. Chong, Filippa Nyberg, Eric F. Morand, David Fivenson, Francois Chasset, Qianyun Li, Michael Schindelar, Effie Pournara, Weihong Yang < PREVIOUS POSTER NEXT POSTER > POSTER 40

Blendability of a Tinted Moisturizer with SPF Across Many Skin Tones Sindhu Garimella, MS; Thu Q. Nguyen, PhD; Christine Emesiani, PharmD; Matthew Meckfessel, PhD < PREVIOUS POSTER NEXT POSTER > POSTER 41

Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 and STOP-HS2 Phase 3 Studies Martina L. Porter, MD, Antonio Martorell, MD, PhD, Christopher J. Sayed, MD, Falk G. Bechara, MD, Hadar Lev-Tov, MD, MAS, Jennifer L. Hsiao, MD, John W. Frew, MBBS, MMed, MSc, PhD, Christos C. Zouboulis, MD, PhD, Joslyn S. Kirby, MD, MS, MEd, Huiling Zhen, PhD, Leandro L. Santos, MS < PREVIOUS POSTER NEXT POSTER >

Bimekizumab Leads to Sustained Flare-Free Status in Moderate-to-Severe Hidradenitis Suppurativa: 3-Year Data from BE HEARD EXT Steven Daveluy, Haley B. Naik, Ziad Reguiai, Sayaka Yamaguchi, Pablo Fernández-Peñas, Bartosz Lukowski, Christina Crater, Nicola Tilt, Antonio Martorell < PREVIOUS POSTER NEXT POSTER > POSTER 43

Bimekizumab Efficacy by Patient Subgroups in Moderate-to-Severe Hidradenitis Suppurativa: 3-Year Phase 3 Results from BE HEARD EXT Christopher J. Sayed, Martina L. Porter, Alejandro Molina-Leyva, Jacek C. Szepietowski, Yosuke Ishitsuka, Evelina van Ree, Christina Crater, Tom Vaux, Georgios Kokolakis < PREVIOUS POSTER NEXT POSTER > POSTER 44

Sofpironium Gel, 12.45% Improves Quality of Life and Patient Global Impression of Severity and Change in Patients with Primary Axillary Hyperhidrosis Neal Bhatia, MD, James Del Rosso, DO, Michael Gold, MD, Martina Cartwright, PhD < PREVIOUS POSTER NEXT POSTER > POSTER 45

Cutaneous Candidiasis as a Manifestation of Systemic Disease in an Immunocompromised Pediatric Patient Emanuel Chew, MD; Jennifer Guadarrama, MD; Hannia Torres, MD < PREVIOUS POSTER NEXT POSTER > POSTER 46

Avapritinib Achieves Durable Improvement in Skin Findings With a Well-Tolerated Safety Profile in Patients With Indolent Systemic Mastocytosis (ISM): Long-term Analyses From the PIONEER Study Karin Hartmann, Cem Akin, Frank Siebenhaar, Sigurd Broesby-Olsen, Hanneke Oude Elberink, Tracy I. George, Hui-Min Lin, Ilda Bidollari, Kate Newberry, Ashley Doyle, Lauren Madigan < PREVIOUS POSTER NEXT POSTER > POSTER 47

The Role of Cosmetic Dermatologists, Aestheticians, and Beauticians in Recognizing and Responding to Mental Health Concerns: A Systematic Review Madeline Ng, Misbah Gaurd, Daanyal Noor Farrukh, Fiza Farrukh < PREVIOUS POSTER NEXT POSTER > POSTER 48